12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARN-509: Phase II data

Data from 93 patients with CRPC in the Phase II portion of an open-label, dose-escalation, U.S. Phase I/II trial showed that once-daily 240 mg ARN-509 was well tolerated. Additionally, 88% of treatment-naïve CRPC patients (n=25), 29% of patients who progressed after treatment with Zytiga abiraterone (n=21) and 91% of non-metastatic CRPC patients (n=47)...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >